Rising Demand in Companion Animal Diagnostics | Market Outlook

According to the report, the global companion animal diagnostics market was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chain, competitive scenario, and regional landscape. The market study is exclusively meant to help the readers with a complete valuation of industry analysis and trends.

Drivers, restraints, and opportunities-

Rise in the prevalence of zoonotic diseases in animals, surge in technological advancements in point-of-care diagnostics, and increase in disposable income levels in the developing regions drive the growth of the global companion animal diagnostics market. On the other hand, lack of skilled veterinary professionals impedes the growth to some extent. However, surge in awareness associated with animal healthcare and increase in adoption of rapid tests and portable instruments in point-of-care diagnostics are projected to create lucrative opportunities in the industry.

The clinical biochemistry segment to dominate by 2031-

Based on technology, the clinical biochemistry segment held around one-third of the global companion animal diagnostics market revenue in 2021, and is expected to lead the trail by 2031. The same segment would also manifest the fastest CAGR of 9.4% from 2022 to 2031. This is attributed to the spike in the number of pet adoptions and surge in awareness related to pet healthcare among pet owners.

The clinical pathology segment to rule the roost-

Based on application, the clinical pathology segment generated the major share in 2021, holding more than one-third of the global companion animal diagnostics market, and is projected to dominate throughout the forecast period. The same segment would also cite the fastest CAGR of 9.2% by 2031, due to rise in the incidence of chronic diseases such as rabies virus, skin diseases, and others.

The dogs segment to maintain the lion's share-

By animal type, the dogs segment contributed to nearly half of the global companion animal diagnostics market share in 2021, and is expected to retain its dominance by 2031. The same segment is also expected to exhibit the fastest CAGR of 8.9% from 2022 to 2031. Increase in the number of companion animals such as dogs across the world and rise in the incidence of zoonotic diseases in dogs are the major factors fueling the segment growth.

North America garnered the major share in 2021-

Based on region, North America held the major share in 2021, generating nearly half of the global companion animal diagnostics market, owing to increase in the prevalence of chronic diseases among these animals. Asia-Pacific, simultaneously, would garner the fastest CAGR of 10.2% by 2031. This is due to surge in the population of companion animals, growing demand for diagnostics services from the livestock industry, and increasing expenditure to restore the health of the animals.

Key players in the industry-

• Thermo Fisher Scientific, Inc
• Zoetis, Inc
• Agrolabo spa
• Biomerieux SA
• Virbac
• Indical Bioscience Gmbh
• Fujifilm Holdings Corporation
• Triviumvet
• Neogen Corporation
• Shenzhen Mindray Animal Medical Technology Co. Ltd
• BioNote Inc
• Creative Diagnostics
• Heska Corporation
• HyTest Ltd
• Idexx Laboratories Inc
• IDvet
• Randox Laboratories Ltd

The report analyzes these key players in the global companion animal diagnostics market. These players have incorporated various strategies such as expansion, new product launches, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in assessing the operating segments, their business performance & product portfolio, and so on.